BRIM closes a $45.8 million rights issue early to accelerate its pipeline of regenerative peptides

BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company focusing on developing regenerative peptides for ophthalmology and degenerative joint diseases, announced today that 22,500 shares have been issued at a premium of NT$65 (~US$2.03), raising a total of NT$1.4625 billion (~US$45.8 million). The rights issue was fully paid on 31st August 2023, four days early compared to the scheduled date of 4th September.

SMi Systems secures UK patent for breakthrough single molecule imaging capabilities

SMi Systems has secured a patent from the UK Intellectual Property Office for the single-molecule imaging technologies that underpin its super-resolution multi-omic platform.

Torx® Software announces global drug discovery collaboration with CDD Vault®

Torx® Software Limited has launched a major international collaboration with CDD Vault, which will create a shared digital ecosystem for drug discovery data

Central California Alliance for Health Selects ZeOmega’s Care Management Solution to Support Whole-Person Care

Central California Alliance for Health (CCAH), just announced they selected ZeOmega’s care management solution to support its 420,000+ Medi-Cal members, including those in the most vulnerable communities. ZeOmega’s platform will enable CCAH to pinpoint the care needs of at-risk members and champion CalAIM’s efforts to provide equitable, person-centered care across California. This partnership also reflects the increased demand for flexible and scalable technology solutions to support government-sponsored healthcare programs across the nation.

New Cell & Gene Therapy Solutions from Form Bio Analyze Billions of Potential Construct Candidates, Reducing Time-to-Clinic

Form Bio, the provider of advanced computational life sciences technology announced today capabilities for cell and gene therapy companies to rapidly model billions of potential construct candidates. With great progress to date but headwinds around safety and manufacturability, Form’s new solutions help therapy developers find the safest and highest yielding versions of their therapies.

Huateng Pharma to Attend CPHI Barcelona 2023

Huateng Pharma will be attending CPhI Worldwide, Booth 3C02, Hall 3.

Launch of high-quality (pre-clinical) enzymes suitable for pre-clinical and process development in mRNA vaccine and therapeutics

Takara Bio Europe has announced the launch of new high-quality grade mRNA production enzymes suitable for pre-clinical and process development in mRNA vaccine and therapeutic manufacturing.

Lonza Upgrades MODA-ES® Module for Enhanced Electronic Batch Record Execution

Lonza has released the MODA-ES® Module v4.0, an upgrade to its electronic batch record (EBR) module that enhances user experience and simplifies integration to expedite product release.

GenNext & SCIEX to Co-Market an Advanced High Order Structure Analysis (HOS) Workflow for Biopharmaceutical Research

GenNext & SCIEX Co-Market an advanced high order structure analysis workflow for biopharmaceutical research to spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics

GenNext Unveils the World’s First Fully Automated Protein Footprinting System at the California Separation Science Society Meeting

GenNext Unveils the World’s First Fully Automated Protein Footprinting System at the California Separation Science Society Meeting The new AutoFox™ System promises to deliver hands-free, high-throughput Hydroxyl Radical Protein Footprinting for sophisticated Higher Order Structural (HOS) analysis

AVIA’s National Generative AI Collaborative Announces New Experts, Enhanced Health System Participation

The Generative AI Strategic Collaborative reveals a slate of 10 clinical, ethics, technology, and regulatory experts for its national consortium

BioIVT Completes XenoTech Integration, Highlights Expanded ADME-Tox Research Services at the North American ISSX Meeting

BioIVT has implemented new tiered ‘fit-for-purpose’ study designs for metabolism, drug-drug interaction, and transporter programs, which utilize their electronic notebook system and automated reports, enabling them to better meet clients’ needs by reducing turnaround time, while maintaining the highest level of scientific expertise and quality.

Amerigo Scientific Releases FSB Solution Products to Expedite Alzheimer’s Disease Research

Lactabico graduates from German Accelerator to bring novel peptide-based drugs to the global market

Lactabico, an innovative biotech startup, has announced its graduation from the prestigious German Accelerator, a leading institution dedicated to propelling the growth of startups in the biotechnology sector.

Intellegens and CPI awarded £1.6m Innovate UK grant to advance manufacture of oligonucleotide therapeutics with machine learning

Intellegens, a company applying machine learning (ML) to accelerate innovation in R&D, has secured a £1.6m grant from Innovate UK, part of UK Research and Innovation (UKRI), to apply ML in the emerging field of oligonucleotide therapies. In collaboration with the Centre for Process Innovation (CPI), the two-year project will augment and validate the company’s ML technology, Alchemite™, as a tool to enhance productivity and yields of oligonucleotide therapeutic manufacture through performance prediction and optimisation of quality control strategies.

Recipharm partners with Ahead Therapeutics to develop rare autoimmune disease therapy

About Recipharm Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical and biopharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical and biologics product development, and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK, and the US and is headquartered in Stockholm, Sweden. For more information on Recipharm and our services, please visit www.recipharm.com About Ahead Therapeutics Ahead Therapeutics is a start-up biotech company that uses proprietary technology to develop treatments for different autoimmune disorders. Ahead Therapeutics has developed an innovative solution based on the use of PS-liposomes containing autoantigens. These liposomes can induce antigen-specific immune tolerance through a biomimetic process, thereby interrupting the autoimmune reaction. Simply by changing the encapsulated autoantigen, Ahead’s technology can address the treatment of different auto-immune diseases: Type 1 Diabetes; Multiple Sclerosis; and Celiac Diseases, among others. For more information, please visit www.aheadtherapeutics.com Recipharm AB Corporate identity number 556498-8425 Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00 www.recipharm.com

Cleveland Diagnostics Announces Prostate Cancer Awareness Month Campaign: ‘A PSA on PSA’

National Initiative to Educate Patients, Drive Awareness, & Raise Funds for ZERO Prostate Cancer; Donation Made for Every Fact Sheet Downloaded at PSAonPSA.com

CD Genomics Revolutionizes Pathogen Discovery with the Launch of Viral Metagenomic Sequencing Service

CD Genomics Launches Mature HLA Typing Solutions Enabling Precision Immune Profiling

Watson-Marlow cased pumps for biotechnology